← Back to Search

Other

H-1337 Eye Drops Safety Study

Phase 1
Waitlist Available
Research Sponsored by D. Western Therapeutics Institute, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy adult male or female subjects
Be older than 18 years old
Must not have
Chronic or acute ophthalmic disease in each eye including but not limited to any form of glaucoma, retinal diseases, clinically significant cataract (primary or secondary)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening through day 9
Awards & highlights
No Placebo-Only Group

Summary

This trial will test how safe it is to use a specific dose of H-1337 eye drops twice a day in both eyes of healthy volunteers.

Who is the study for?
This trial is for healthy adult men and women with good eye and overall health. Participants should have no significant medical or eye history that could affect the study.
What is being tested?
The study is testing the safety of a new treatment called H-1337 at a concentration of 1%, administered twice daily in both eyes, on healthy volunteers.
What are the potential side effects?
Since this is an early-stage trial to test safety, specific side effects are not yet known but may include irritation, discomfort, or other changes in vision or eye health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a healthy adult.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any long-term or recent eye diseases like glaucoma or significant cataracts.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening through day 9
This trial's timeline: 3 weeks for screening, Varies for treatment, and screening through day 9 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Treatment-Emergent Adverse Events Reporting [Safety and Tolerability]

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: H-1337 1.0% Ophthalmic Solution b.i.d.Experimental Treatment1 Intervention
One drop H-1337 twice daily in the both eyes for 7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
H-1337 1.0%
2023
Completed Phase 2
~220

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

D. Western Therapeutics Institute, Inc.Lead Sponsor
1 Previous Clinical Trials
201 Total Patients Enrolled
1 Trials studying Glaucoma
201 Patients Enrolled for Glaucoma
~11 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top